BioNTech SE (BNTX) Net Income towards Common Stockholders (2018 - 2025)

BioNTech SE has disclosed Net Income towards Common Stockholders across 8 years of filings, most recently posting -$174.4 million for Q4 2025.

• Net Income towards Common Stockholders for Q4 2025 came in at -$174.4 million, down 162.88% year-over-year; the trailing twelve-month figure through Dec 2025 was -$1.1 billion (down 32.16% YoY), and the FY2025 annual result was -$1.1 billion, down 47.92% from the prior year.
• Net Income towards Common Stockholders came in at -$174.4 million for Q4 2025 at BioNTech SE, down from $91.3 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $4.2 billion in Q1 2022 to a low of -$865.6 million in Q2 2024.
• The 5-year median for Net Income towards Common Stockholders is $298.8 million (2024), against an average of $1.0 billion.
• Across the five-year window, Net Income towards Common Stockholders surged 114544050.96% in 2022 and plunged 317.5% in 2024, its largest moves.
• BioNTech SE's Net Income towards Common Stockholders stood at $3622.0 in 2021, then soared by 114544050.96% to $4.1 billion in 2022, then sank by 88.13% to $492.7 million in 2023, then slumped by 43.72% to $277.3 million in 2024, then plunged by 162.88% to -$174.4 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$174.4 million (Q4 2025), $91.3 million (Q3 2025), and -$474.1 million (Q2 2025), per Business Quant data.